A Phase II Randomized, Placebo Controlled, Double-blind, 4 Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Ulcerative Colitis.
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs SHR 0302 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Reistone Biopharma
- 26 Jun 2019 Planned End Date changed from 30 Jul 2020 to 30 Sep 2020.
- 26 Jun 2019 Planned primary completion date changed from 30 Apr 2020 to 31 Jul 2020.
- 14 Jun 2019 According to a Reistone Biopharma media release, first patient has been dosed in this study.